)
Visual
earnings real time
Verastem (VSTM) investor relations material
Verastem Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary2 Dec, 2025
Launch performance and market dynamics
Avutometinib launched for low-grade serous ovarian cancer, targeting a rare, underserved population, with a focus on being the first switch after current therapies fail.
Early launch skewed toward academic centers due to KOL involvement, but community uptake is increasing as GPO and distributor contracts are established.
Market consists of roughly half the patients at 100 major institutions, with the rest in large community practices; GynOnc specialists drive most prescribing.
Early approval required rapid operational adjustments, but infrastructure is now in place to support ongoing growth.
NCCN guideline updates expected after the new year may accelerate uptake, with strong reimbursement and active copay assistance programs supporting access.
Clinical development and trial updates
RAMP 301 trial enrollment was increased by 29 patients after interim analysis indicated promising results for both wild type and mutant cohorts.
Initial PFS results from RAMP 301 are expected in the second half of 2027, with guidance to be refined as the event-driven trial progresses.
Investigator's choice comparator arm in RAMP 301 uses five FDA-agreed therapies, with improved design over prior studies by prospectively separating wild type and mutant patients.
KRAS inhibitor landscape and competitive positioning
G12D inhibitor is positioned as potentially best-in-class, binding both on- and off-state KRAS with high affinity, unlike competitors that target only one state.
Preclinical and clinical data show superior durability and response rates compared to RevMed, with 69% response in lung and 58% in second-line pancreatic cancer.
Tolerability is managed through feeding and prophylactic antiemetics, resulting in minimal high-grade GI side effects in trials.
Combination strategies include cetuximab for colorectal and chemo/chemo-IO for lung, aiming for rapid entry into frontline settings.
What drives LGSOC market evolution in 2026?
Explain G12D's 'best in class' mechanism
Outline path to frontline KRAS G12D indications
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Verastem earnings date
Q4 202516 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Verastem Inc is a development-stage biopharmaceutical company primarily focused on the development and commercialization of new medicines aimed at improving the lives of patients diagnosed with cancer. The company is engaged in advancing a pipeline of novel small-molecule drugs that target critical signaling pathways involved in cancer cell survival and tumor growth. These pathways include RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition, which are central to the company's research and development efforts. The company is headquartered in Needham, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage